bspt salt | 38116-89-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: bspt salt
• 英文别名: 6-[3-(1,3-benzothiazol-2-yl)-5-[(E)-2-phenylethenyl]tetrazol-3-ium-2-yl]-2,3-dihydrophthalazine-1,4-dione;chloride
• CAS: 38116-89-1
• 化学式: C24H16ClN7O2S
• 分子量: 501.9
• InChiKey: ZPGCKYFKHCIWHR-RSGUCCNWSA-N

物化性质

• 熔点：
  254 ℃
• 溶解度：
  Soluble in water, ethanol, N , N -dimethyl- formamide
• 最大波长(λmax)：
  300 nm

计算性质

• 辛醇/水分配系数(LogP)：
  0.72
• 重原子数：
  35
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  127
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• WGK Germany：
  3

文献信息

• Stable reagent for formazan-based assay
  申请人：Kirkegaard & Perry Laboratories, Inc.

  公开号：EP0971037A2

  公开（公告）日：2000-01-12

  This invention relates to a stable, all-in-one aqueous reagent comprising 5-methyl-phenazinium methyl sulfate (phenazine methosulfate (PMS)), nitric acid and a metal salt wherein the metal is selected from the group consisting of vanadium, manganese, cobalt, and mixtures thereof, useful in assays which use alkaline phosphatase as a reporter enzyme and a reduction of a tetrazolium salt to a formazan as a detection/signaling system for detecting or quantifying a target substance in a sample.

  本发明涉及一种稳定的多合一水基试剂，由 5-甲基酚嗪甲基硫酸盐（酚嗪甲硫酸盐（PMS））、硝酸和金属盐组成，其中金属选自由钒、锰、钴和它们的混合物组成的组、钴及其混合物组成的组中，适用于使用碱性磷酸酶作为报告酶，并将四唑盐还原为甲臢作为检测/信号系统来检测或定量样品中的目标物质的检测方法。
• DRUGS FOR IMPROVING THE PROGNOSIS OF BRAIN INJURY AND A METHOD OF SCREENING THE SAME
  申请人：Japan Science and Technology Agency

  公开号：EP1535629A1

  公开（公告）日：2005-06-01

  There are provided a compound for treatment or prevention of brain injury caused by diseases such as cerebrovascular disorder, brain degenerative disease and demyelinating disease and a method for screening the same. Brain injury in which prostaglandin D2 is participated is treated or prevented by inhibition of hematopoietic prostaglandin D synthase induced in microglia cell or macrophage of brain injury area by diseases such as cerebrovascular disorder, brain degenerative disease or demyelinating disease or by inhibition of activation of prostaglandin D receptor expressed in astroglia cell around the injured area. There is also provided a method of testing those pharmaceutical substances using a transgenic mouse in which human hematopoietic prostaglandin D synthase is expressed in large amounts.

  提供了一种用于治疗或预防脑血管疾病、脑变性疾病和脱髓鞘疾病等疾病引起的脑损伤的化合物及其筛选方法。 通过抑制脑血管疾病、脑变性疾病或脱髓鞘疾病等疾病在脑损伤区域的小胶质细胞或巨噬细胞中诱导的造血前列腺素 D 合成酶，或通过抑制损伤区域周围星形胶质细胞中表达的前列腺素 D 受体的活化，治疗或预防前列腺素 D2 参与的脑损伤。此外，还提供了一种利用大量表达人造血前列腺素 D 合酶的转基因小鼠检测这些药物的方法。
• Drugs for improving prognosis of brain injury
  申请人：Japan Science and Technology Agency

  公开号：EP1598065A2

  公开（公告）日：2005-11-23

  A compound for treatment or prevention of brain injury caused by diseases such as cerebrovascular disorder, brain degenerative disease and demyelinating disease. The compound comprises an antagonist for the prostaglandin D receptor as an effective ingredient. Brain injury in which prostaglandin D2 is a factor is treated or prevented by inhibition of hematopoietic prostaglandin D synthase induced in microglia cell or macrophage of brain area by diseases such as cerebrovascular disorder, brain degenerative disease or demyelinating disease or by inhibition of activation of prostaglandin D receptor expressed in astroglia cell around the injured area.

  一种化合物，用于治疗或预防由脑血管疾病、脑变性疾病和脱髓鞘疾病等疾病引起的脑损伤。该化合物的有效成分包括前列腺素 D 受体拮抗剂。 通过抑制脑血管疾病、脑变性疾病或脱髓鞘疾病等疾病在脑区小胶质细胞或巨噬细胞中诱导的造血前列腺素 D 合成酶，或通过抑制损伤区周围星形胶质细胞中表达的前列腺素 D 受体的活化，治疗或预防以前列腺素 D2 为因素的脑损伤。
• Dental composition
  申请人：3M Innovative Properties Company

  公开号：EP2052712A1

  公开（公告）日：2009-04-29

  The present invention relates to a bacteria detecting dental composition comprising a solution of at least one electron acceptor and at least one electron donor wherein the electron acceptor and the electron donor are selected that in the solution itself the electron donor can not transmit reduction equivalents to the electron acceptor and wherein the dental composition is substantially free of compounds that enable or facilitate the electron transmission between the electron acceptor and the electron donor. The present invention further relates to the use of a composition comprising a solution of at least one electron acceptor and at least one electron donor wherein the electron acceptor and the electron donor are selected that in the solution itself the electron donor can not transmit reduction equivalents to the electron acceptor and wherein the composition is substantially free of compounds that enable or facilitate the electron transmission between the electron acceptor and the electron donor for site-directed intraoral detection of bacteria.

  本发明涉及一种细菌检测牙科组合物，该组合物包含至少一种电子受体和至少一种电子供体的溶液，其中电子受体和电子供体被选择为在溶液本身中电子供体不能向电子受体传递还原当量，并且该牙科组合物基本上不含能够或促进电子受体和电子供体之间电子传递的化合物。 本发明进一步涉及一种由至少一种电子受体和至少一种电子供体的溶液组成的组合物的用途，其中电子受体和电子供体被选择为在溶液本身中电子供体不能向电子受体传递还原当量，并且该组合物基本上不含能够或促进电子受体和电子供体之间电子传递的化合物，用于口腔内定点细菌检测。
• METHOD FOR DETERMINING THE PRODUCTION OF REACTIVE OXYGEN SPECIES IN A CELLULAR POPULATION
  申请人：Universitat Autònoma De Barcelona

  公开号：EP2637019A1

  公开（公告）日：2013-09-11

  The invention relates to a method for determining the production of reactive oxygen species in a cellular population. The invention also relates to a method for determining the need for an antioxidant treatment of a male subject, and to a method for identifying a substance that can reduce the reactive oxygen species in a cellular population.

  本发明涉及一种确定细胞群中活性氧产生情况的方法。本发明还涉及一种确定男性受试者是否需要抗氧化剂治疗的方法，以及一种确定能够减少细胞群中活性氧的物质的方法。